Few immunotherapists would accept the concept of a single vaccination inducing a therapeutic anticancer immune response in a patient with advanced cancer. But what is the evidence to support the ''more-is-better'' approach of multiple vaccinations? Because we are unaware of trials comparing the effect of a single vaccine versus multiple vaccinations on patient outcome, we considered that an anticancer immune response might provide a surrogate measure of the effectiveness of vaccination strategies. Because few large trials include immunologic monitoring, the majority of information is gleaned from smaller trials in which an evaluation of immune responses to vaccine or tumor, before and at 1 or more times following the first vaccine, was performed. In some studies, there is convincing evidence that repeated administration of a specific vaccine can augment the immune response to antigens contained in the vaccine. In other settings, multiple vaccinations can significantly reduce the immune response to 1 or more targets. Results from 3 large adjuvant vaccine studies support the potential detrimental effect of multiple vaccinations as clinical outcomes in the control arms were significantly better than that for treatment groups. Recent research has provided insights into mechanisms that are likely responsible for the reduced responses in the studies noted above, but supporting evidence from clinical specimens is generally lacking. Interpretation of these results is further complicated by the possibility that the dominant immune response may evolve to recognize epitopes not present in the vaccine. Nonetheless, the Food and Drug Administration approval of the first therapeutic cancer vaccine and recent developments from preclinical models and clinical trials provide a substantial basis for optimism and a critical evaluation of cancer vaccine strategies.
T raditional views regarding cancer vaccines hold that persistence of a therapeutic anti-tumor response would be best accomplished by providing ''booster'' vaccinations. This postulate is based in large part on a well-established tenet of immunology based on the success of vaccines to protect uninfected naive individuals from subsequent exposure to specific infec-tious agents or their toxins. In these cases, a priming vaccination is typically followed by a series of booster vaccines that expand the pool of memory B and T cells. 1, 2 However, some vaccines for infectious disease provide protection with a single dose (influenza, smallpox). This is similar to many preclinical tumor vaccine studies where a single vaccination can prime tumor-specific immune responses that provide protection from a subsequent tumor challenge. In most models, the ability of a single vaccine to provide therapeutic immunity has correlated with a tumorspecific type 1 immune response, where CD8 T cells secrete interferon F (IFN-F) and/or tumor necrosis factor > (TNF->). 3 Classic tumor immunotherapy studies frequently start with a single immunization with irradiated immunogenic tumor cells or tumor cells mixed with Corynebacterium parvum, followed by serial immunization with live tumor cells to generate ''immune'' mice. 4Y7 Immune responses in mice that reject tumor challenges are likely to be substantially different from mice receiving repetitive vaccinations with a vaccine that does not contain viable tumor cells. Recently, our group reported that T cells from thricevaccinated mice were significantly less effective in adoptive transfer studies than T cells from mice receiving a single vaccination. 8 A striking difference observed in multiply vaccinated animals was an increase in the number of CD4+ regulatory T cells (Tregs). Elimination of these regulatory cells during the second and third vaccinations resulted in a recovery of therapeutic efficacy. At the same time, a number of large phase III clinical trials found that patients receiving multiple vaccines had significantly worse outcomes than control arms. This included 2 adjuvant studies where patients were randomized to receive a vaccine composed of 3 allogeneic melanoma cell lines plus bacille Calmette-Guérin (BCG) versus BCG alone. 9, 10 In a study, 1166 patients with stage III melanoma were enrolled. In a second study, 496 patients with stage IV melanoma were enrolled. At the interim analysis, both studies were halted because of significantly worse outcomes in the tumor vaccine arms. 11 In another study, 1314 stage II melanoma patients were randomized to observation or vaccination with a ganglioside vaccine. 11, 12 When an interim analysis was performed, the vaccine arm exhibited a significantly worse survival than observation, and the trial was stopped. These results moved us as well as many in the field to evaluate the rationale for repetitive vaccinations. 8, 10, 13 As noted above, one setting where multiple ''booster''doses are effective is in the prevention of infectious disease. An obvious difference between vaccines for the prevention of infectious disease and the immunotherapy of cancer is that, in the setting of cancer, vaccines are not yet preventive, and therapeutic vaccines are not administered to naive individuals but to patients who have lived with their cancer for months to years and frequently have substantial tumor burden at the time of vaccination. In addition, unlike vaccines for infectious disease, which contain foreign antigens to which the host is not immunologically tolerant, most cancer vaccines contain antigens normally expressed by the host, which provides an opportunity for the host to develop immunologic tolerance. Finally, whereas tumor cells are continuously undergoing mutations that improve the chances of escaping an immune response, the success of many vaccines for infectious disease likely relates to the stability of the antigenic repertoire. 14 We consider that these observations provide insight into why clinical trials of therapeutic cancer vaccination have been less effective than vaccines for prevention of infectious disease.
PROTECTION AGAINST PATHOGENS OFTEN REQUIRES MULTIPLE VACCINATIONS
Given the success of booster vaccines for infectious diseases, a review of the literature of immune responses that correlate with protective immunity to pathogens is warranted. The Food and Drug Administration (FDA) has approved more than 70 vaccines for distribution in the United States; of these, less than half protect with a single vaccination (influenza, smallpox, pneumococcal), and the majority require 1 or more boosting vaccinations (hepatitis, measles, encephalitis, tetanus). 15 The infectious disease field has a limited number of surrogates for protective immunity induced by vaccination. As an example, the major correlate of protection for smallpox vaccination, which historically has been administered by scarification with a bifurcated needle, is measured by the appearance of a primary vesicle at the vaccination site. 16 This pustule has been one of the best correlates to vaccine protection; however, it is highly specific for the route of vaccination on the skin's surface. 1, 17 Antibodies reduce disease by opsonization, antibody-dependent cellular cytotoxicity, and complement-dependent cytotoxicity to neutralize pathogens and eliminate pathogen-infected cells. 18 Monitoring the antibody response can provide an indication of vaccine-induced protective immunity. For the yellow fever virus, the induction of a yellow fever plaque neutralizing antibody of log greater than 0.7 conferred protection in nonhuman primate models and is widely accepted as evidence of protective immunity. 19 Antibodies that developed following tetanus vaccination have been shown to be protective at levels as low as 0.01 IU/mL. 2 However, neutralizing antibodies wane over time after vaccination with tetanus and hepatitis B, and therefore, booster vaccinations are suggested. 1, 20 Memory B-cell responses do not seem to correlate with serum levels of vaccine-specific antibodies; however, they do correlate with protection from chronic viral infections. 1 Because of the ''chronic'' nature of cancer immunity, it is possible that memory B cells could be an important aspect for both cancer vaccine monitoring and the therapeutic effects of immunotherapy. Certain viral infections are more likely to elicit vaccine-specific cellular responses than others. The efficacy of smallpox vaccination, which eradicated smallpox in 1980, is thought to be a result of vaccine-induced CD4 and CD8 T-cell responses nearly identical to those observed following smallpox infection. 21 This possibility has pushed the infectious disease field to develop vaccines that mimic cellular immunity to natural infection. 22 Induction of polyfunctional T cells that produce IFN-F, TNF->, interleukin 2 (IL-2), and macrophage inflammatory protein 1A correlates with viral protection, vaccinia vaccination, and prime-boost regimens using attenuated vaccinia virus and therefore is another measure of vaccine efficacy. 23 Thus, for many infectious diseases, booster vaccines augment immune responses that correlate with protection from that disease. The human papilloma virus (HPV) vaccine is administered as a priming dose followed by 2 booster vaccinations and is one of the best examples of a multiply administered preventive vaccine that decreases incidence of cervical cancer. 24 What is the evidence that administration of additional booster vaccinations augments the anti-tumor im-mune response in the therapeutic setting? To address this question, we reviewed clinical trials that reported immunologic monitoring at 2 or more time points. We included some reports that did not include monitoring but translated concepts or had some clinical outcome we felt contributed to the review. A table summarizing the effect of specified vaccination strategies on the anticancer immune response is provided (Table 1 ).
Peptide Vaccines: Gp100 Peptide Vaccine in Metastatic Melanoma
Melanoma differentiation antigens have been the subject for many of the peptide vaccine trials. Among this group, melanocyte lineageYspecific antigen glycoprotein (gp)100 received a great deal of attention because its expression is limited to pigmented cells; it was a common target of tumor-infiltrating lymphocyte (TIL) cultures, and the adoptive transfer of gp100-reactive TILs was associated with objective clinical responses. 55Y57 The largest number of gp100 studies were performed with the gp100 (209-2M) peptide, a peptide modified to express a methionine at the second position, which increases the affinity for its major histocompatibility complex (MHC) molecule and leads to superior T-cell activation. Vaccination with this altered peptide ligand could prime and expand T cells capable of recognizing native peptide and human leukocyte antigen A2+ (HLA-A2+) tumor cells that expressed gp100. 58 An analysis of published results from 8 trials using gp100 peptide alone to immunize 90 patients with metastatic melanoma identified 1 objective clinical response for an overall response rate of approximately 1%. 25 Similarly in a recent study by Hodi et al, 59 1.5% of patients (2/136) had a PR to gp100 peptide treatment alone. A trial giving up to 10 gp100 (209-2M) peptide vaccinations, at 3-week intervals, showed that gp100-specific T-cell frequency increased in all patients after 1 or 2 vaccinations, and these patients had T cells expressing IFN-F. Only 1 patient was analyzed after additional vaccinations, and that patient showed a diminished gp100-specific T-cell frequency. 26 
Gp100 Peptide Vaccine (CD8 Epitope) in the Adjuvant Setting
Given the possible immunosuppressive properties of metastatic disease, our group administered the gp100 (209-2M) peptide vaccine to resected stage IYIII melanoma patients with no evidence of disease. 29 An HPV peptide was included as a control. Although the trial was not powered to detect an effect on survival, the effect of vaccination at 2-or 3-week intervals on gp100-specific T cells was assessed. No patient had a detectable level of gp100-specific T cells before vaccination. At 6 months after the first vaccination, 96.5% (28/29) of vaccinated patients developed a detectable response. There was no significant difference between tetramer-binding T cells observed with vaccination at 2-or 3-week intervals. Evaluation of the response to the foreign HPV peptide showed that the median responses to gp100 and the HPV peptides were similar (P G 0.92). Although numbers were small, patients older than 60 years had a significantly (P G 0.0055) lower response to peptide vaccination than did younger patients.
PEPTIDE-SPECIFIC T-CELL NUMBERS INCREASE WITH ADDITIONAL VACCINE CYCLES
Two subsequent studies in patients with high risk of melanoma recurrence evaluated vaccination with 2 CD8 epitopes from tumor associated antigens, gp100 (209-2M), and tyrosinase 368Y376 (370D). In the first study, the peptides were emulsified separately in incomplete Freund adjuvant (IFA) and injected subcutaneously in different extremities. Seventeen percent of patients exhibited strong responses to vaccination, defined as greater than 10% circulating tetramer + CD8 T cells. In the second study, the peptides were mixed together and injected at 1 site. In this case, there were no tetramer responses to gp100, which was significantly (P G 0.01) less than that observed for the preceding study. In contrast, T-cell responses against tyrosinase were increased, demonstrating the complexity of the immune system's response to these altered peptide ligands. 30 In both studies, the authors performed a careful kinetic analysis of peptide-reactive T-cell frequencies over time. Although gp100 tetramer-binding T cells were detected in some patients in all cohorts after a single vaccine cycle, the mean number of peptidereactive T cells, identified by ELISpot or tetramer, continued to increase with each vaccine. In this setting, multiple vaccinations with class I binding epitopes in IFA augmented the priming and expansion of vaccine-specific T cells. Patients receiving a gp100 class IYrestricted CD8+ epitope alone generated longterm memory T cells that were reactivated by booster vaccines. Unfortunately, a high frequency of peptide-specific T cells against a single epitope was not protective as tumors progressed even in patients with greatly elevated levels of peptide-specific T cells. 31 The evolution of escape mutants that lost antigen or HLA or had defects in antigen-processing pathways were not ruled out; however, other possibilities could be responsible for tumor progression, including a failure of T cells to traffic to tumor sites and/or retain tumor destructive function.
VACCINATION WITH TUMOR-ASSOCIATED CD4 PEPTIDE EPITOPES REDUCES THE CD8 RESPONSE
Another possibility, supported by preclinical studies, is that CD8 T cells primed with class I epitopes, in the absence of CD4 T-cell help, may be less effective mediators of long-term anticancer immunity. 60 A possible approach to rectify this is to include class II peptide epitopes recognized by tumor-reactive CD4 T cells. One report analyzed results from 2 consecutive, nonrandomized studies comparing the immune response to vaccination with a class IYrestricted peptide of gp100 versus immunization with both a class IY and a class IIYrestricted peptide from the same antigen. Two vaccinations with the class IYrestricted peptide alone immunized 95% (21/22) of patients to the specific peptide. In contrast, vaccination with both class IY and class IIYrestricted gp100 peptides immunized only 50% of patients (P G 0.005), and the degree of peptide-specific immunity was reduced by including the class II peptide (P G 0.01). 32 A recent 168-patient randomized multicenter study used a vaccine consisting of 12 class I MHCYrestricted melanoma peptides (12 MPs) in combination with either nonspecific tetanus helper peptide or 6 melanoma-associated helper peptides. In addition, these patients were randomized to receive prevaccine treatment with 300 mg/m 2 cyclophosphamide or no chemotherapy. Similar to the study by Phan et al, 32 patients receiving both the CD8 and CD4 melanoma-specific peptides had significantly weaker CD8 T-cell responses than patients receiving the ''nonYtumor-specific'' tetanus help. However, patients receiving the class IIYrestricted melanoma peptide did generate CD4 T-cell responses to those epitopes. The dose and schedule of cyclophosphamide had no effect on T-cell responses to vaccine or on overall survival at 3 years. 33 Why did the presence of tumor-specific help result in significantly weaker CD8 T-cell responses to vaccine? Although there is a possibility that the CD4 epitopes increased Tregs, pilot studies by Phan et al 32 found no differences in Treg numbers before and after vaccination. However, this does not rule out skewing of the Treg pool to include more vaccine antigenspecific Tregs. Another possibility is that the presence of tumorspecific/associated CD4 epitopes supports the spreading of the immune response to epitopes or antigens other than those included in the vaccine. This epitope spreading would not be picked up by the peptide-specific assays used to monitor the immune response. However, there was no difference in overall survival between the 2 groups at 3 years, suggesting that there was not a striking difference in the efficacy of either strategy.
Long Peptides: Composition Influences Booster Vaccine Effectiveness
An alternative vaccine strategy is to use peptides that are longer (25Y35 amino acid [aa]) than the length of the MHCbinding groove. One example of this is a trial that used 13-aalong peptides that covered the entire sequence of HPV E6 and E7 proteins to vaccinate end-stage cervical cancer patients. Groups included patients receiving both E6 and E7 peptides at 1 site versus E6 peptides in 1 limb with E7 in a second limb. Whereas the median immune response to HPV E6 was not different for either group, the median response to HPV E7 was substantially augmented by separating the vaccines. When peptides for both HPV E6 and E7 were combined, 3 or 4 vaccines uniformly resulted in a lower frequency of peptide-specific IFN-FYproducing T cells than observed after only 2 vaccines. This was not true for patients who were vaccinated with E6 and E7 peptides in different limbs. In this setting, 3 or 4 vaccinations increased the number of tumorspecific functional T cells over that observed before treatment or after 2 vaccinations. 40 There is not a clear understanding of why the responses developed as they did, and given the low objective response rate, there was no opportunity to correlate immunologic effects with clinical response. One thing is clearVnumerous studies have shown that vaccination with a single peptide or pools of class IY or IIYbinding peptides in Montanide does not generate therapeutic immune responses.
HER2/NEU HELPER EPITOPE VACCINES WITH GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR
Will addition of an adjuvant increase the immune response to vaccination? Early gene transfer experiments in mice identified granulocyte macrophage colony stimulating factor (GM-CSF) as the ''optimal''single cytokine for eliciting an anti-tumor immune response when comparing vaccination with a whole panel of cytokine-secreting tumor cell lines. 61 Based on these observations, and the availability of GM-CSF, it has been used as an adjuvant in numerous clinical trials. Peptides derived from Her2/neu, a self-protein overexpressed by many human adenocarcinomas, are immunogenic in humans. Disis and colleagues 38 enrolled 64 patients with Her2/neu+ breast cancer, ovarian cancer, or non-small cell lung cancer (NSCLC) onto a 3-arm trial. Only patients with no evidence of disease or stable disease were eligible for this innovative design that included class IYbinding motifs ''inside'' the class II motif sequences. If patients were HLA-A2+, they received a vaccine consisting of three 14-to 18-aa helper epitopes that also contained HLA-A2Ybinding motifs. Patients who were HLA-A2 negative were randomized to receive helper epitopes derived from either the intracellular domain (ICD) or the extracellular domain of Her2/ neu. All vaccines were mixed with 100 to 125 Kg GM-CSF and administered intradermally monthly for 6 months to the same regional area. No Montanide was used. The immunologic monitoring of the patients on this trial was extensive, with blood draws occurring at monthly intervals for 1 year. 38, 39, 44, 62, 63 Although 92% of patients generated a T-cell response to Her2/neu, and the estimated probability of developing a T-cell response to Her2/neu peptide at some time point increased with each additional vaccination; the magnitude of the proliferative response frequently peaked early and diminished while still receiving vaccinations. However, some level of immunity was maintained in the long term after vaccination. One notable observation was that patients who responded early to vaccination (vaccines 1Y3) tended to exhibit stronger stimulation indices to peptide stimulation than those responding after 4 to 6 vaccines. The probability of broadening the immune response to protein-specific immunity took more time. This broadening of the immune response to include components of the protein not included in the vaccine, frequently defined as epitope spreading, occurred in the 6-month follow-up period when no vaccines were given.
MELANOMA HLA CLASS I RESTRICTED (CD8 EPITOPES) WITH GM-CSF AND/OR IFN->2B
In a study similar to that reported above, 121 patients with resected melanoma stage IIB-IV were randomized to receive 12 MPs in combination with a tetanus helper peptide in Montanide with or without GM-CSF. In this study 110 Kg of GM-CSF was mixed into Montanide with the intent to provide slow continuous release of cytokine at the vaccine site. Surprisingly, the GM-CSF group had significantly fewer patients with CD8+ T-cell responses to 12 MPs (34% vs 73%, P G 0.001) and fewer patients with CD4 response to tetanus. Overall survival at 3 years was higher in the group not receiving the very-low-dose GM-CSF (76% vs 52%), but this was not significantly different. 54 In another melanoma study, 3 HLAYclass IYrestricted peptides, tyrosinase, gp100, and MART-1, were used as a vaccine in HLA-A2Ypositive patients who received peptides alone or in combination with GM-CSF (250 Kg/d Â 14 days), at a higher dose than that used above, and/or IFN->2b. Overall immune response as measured by ELISpot after 3 vaccinations was 21.2% (14/66) to any of the vaccine peptides. However, at a later time point when patients had received more vaccinations, the percentage of patients with detectable peptide-specific responses increased to 37% (20/54) .In contrast to the report noted above, in this study treatment with GM-CSF or IFN-> slightly increased the immune response rate, but these differences were not significant. Analysis of the 115 patients enrolled in this study indicated that patients with an immune response to the vaccine had significant improvement in median overall survival compared with patients who did not have an immune response, 21.3 versus 13.4 months (P = 0.046). 35 There were no significant differences in overall survival between patients receiving GM-CSF and/or IFN->2b. Although the GM-CSF dose used in the study of Slingluff et al 64 was associated with a significantly reduced immune response rate to the 12 MPs, the total dose of GM-CSF was very small (110 Kg). While their intent was to provide slow release of GM-CSF at the vaccine site, we raise the possibility that insufficient GM-CSF was released and therefore failed to provide an adjuvant effect. But that does not explain why the response rate was inferior to that of Montanide alone. Nonetheless, patients receiving a substantially higher dose of GM-CSF each day for 2 weeks after vaccination did not exhibit a reduced T-cell response to vaccination.
Whole Cell Vaccines: GM-CSF Gene Modified Autologous Tumor Vaccines
Anti-tumor T-cell cytokine responses were evaluated in 10 patients among 29 patients vaccinated with autologous melanoma cells engineered, using a retroviral vector, to secrete GM-CSF (range of GM-CSF secretion, 84Y965 ng/10 6 per 24 hours). 51 Although not fully controlled for tumor specificity, results from 9 patients suggest that repeated vaccinations augmented the IL-3, IL-4, IL-5, and GM-CSF cytokine responses to autologous tumor. Interferon-F and TNF-> responses were not observed. Although a pattern of dense lymphocytic infiltrates was observed in posttreatment tumor biopsies, no objective clinical responses were observed. The augmentation of type 2 (IL-3, IL-4, and IL-5) cytokine responses might be considered a negative indication for performing multiple vaccines, because preclinical trials have generally found that vaccines inducing a type 2 cytokine response were nontherapeutic. A subsequent trial of 33 metastatic melanoma patients treated with irradiated autologous melanoma cells transduced with an adenoviral vector encoding GM-CSF (median of GM-CSF secretion, 534 ng/10 6 per 24 hours) resulted in successful immunization of 29 patients. One complete response (CR), 1 partial response, and 1 mixed response were observed, and at 36 months after vaccination, 29% (10/35) of patients were alive, and 4 had no evidence of disease. All patients had a substantial number of dendritic cells (DCs), macrophages, eosinophils, and B and T cells at the site of vaccination, which correlated with tumor destruction. An interesting observation was the apparent coordinated T-and B-cell response with large numbers of plasma cells secreting antibody in the postvaccine biopsies. Although all patients developed antibodies reactive with the adenovirus used for vaccine transduction, the possible anti-tumor reactivity of antibody was not discussed, and tumor-specific T-cell responses were not assessed. 52 One difference between these 2 trials was the use of different viral vectors. In the first trial, a retroviral vector was used, whereas the second trial, where clinical responses were observed, used an adenoviral vector.
An adenoviral vector was also used to transduce a GM-CSF construct into autologous NSCLC cells for use as a vaccine. In this study, 3 CRs were reported for 33 patients vaccinated. 65 In each case, these patients were heavily pretreated. Post hoc analysis of these data showed a significant correlation (P G 0.03) with the capacity of GM-CSF vectorYmodified autologous tumor vaccine to secrete a modest level of GM-CSF (940 ng/10 6 cells per 24 hours) and increase patient survival. 65 Analysis of anti-tumor responses was not reported. The 9% CR rate in this small group of patients provided some measure of enthusiasm for this approach, but generating autologous vaccines is technically difficult and, although within the scope of some academic medical centers, is not an easily commercialized product. For these reasons, allogeneic GM-CSFYsecreting vaccines were considered an attractive candidate for treatment because of standardized transduction efficacy and off-the-shelf availability.
ALLOGENEIC GENEYMODIFIED CELLS USED AS A VACCINE
Based on the complete remission seen after vaccination with an autologous NSCLC vaccine, a second NSCLC study that used an allogeneic K562 cell line, genetically engineered to secrete GM-CSF, as a bystander source of GM-CSF was begun. The vaccine comprised a mixture of isolated autologous tumor cells and allogeneic GM-CSFYsecreting bystander cells (K562); the idea being that the bystander cells would produce GM-CSF at the site of the vaccine without having to gene-modify the autologous tumor. There were no objective clinical responses in 49 vaccinated patients. Besides the addition of K562 bystander cells, another difference in these 2 trials was the amount of GM-CSF secreted, which, on average, was 25 times higher with the K562 bystander cells than in the original trial with 3 CRs. 66 No tumor-specific immunologic monitoring was performed in these studies.
An alternative to mixing bystander cells that secrete GM-CSF with autologous tumor cells to generate a vaccine is to transduce GM-CSF expression vectors, or the cytokine of interest into allogeneic tumor cells of the same histology as the patient to be treated. These cells would presumably share antigens with the patient's tumor cells but could be used where it is difficult or impossible to obtain autologous tumor. Prostate cancer is a good candidate for this off-the-shelf approach as it metastasizes to the bone, and it is virtually impossible to isolate sufficient tumor cells for autologous vaccine production. Prostate GVAX is composed of 2 allogeneic yet histologically distinct prostate tumor cell lines, PC3 and LNCAP, both of which are transduced to secrete GM-CSF. Phase I/II trials in patients with advanced disease were performed, with prostate GVAX vaccine administered at a low (100 Â 10 6 cells 28 days Â 6), medium (200 Â 10 6 14 days Â 12), or high (300 Â 10 6 14 days Â 12 and 500 Â 10 6 Â 1) dose with corresponding survival of 23, 20, or 34.9 months, respectively. 67 In another trial, patients were treated with a 500 Â 10 6 cell priming dose and 12 booster vaccinations with 100 Â 10 6 or 300 Â 10 6 GVAX cells, biweekly for 6 months. Progression-free survival assessed by bone scans was 2.8 and 5 months with low-and high-dose vaccines, respectively. 68 Despite promising phase II results, phase III trials comparing chemotherapy (docetaxel and prednisone) to GVAX were prematurely terminated based on the results of a previously unplanned futility analysis, which determined that the study had less than a 30% chance of meeting its predefined primary endpoint of improvement in overall survival. Higano and colleagues 67 reported in early 2009 that although the median survival was similar in both groups, the follow-up Kaplan-Meier survival curve shows that patients receiving GVAX were crossing above patients treated with docetaxel and prednisone at approximately 22 months. While the follow-up is ongoing, this separation in the curves raises the possibility that the GVAX vaccine strategy could have benefit for a subset of patients. No T-cell monitoring was performed on these patients.
WHOLE-CELL VACCINATION WITH GM-CSF PROTEIN HAD VARIED RESPONSE
Other studies have combined GM-CSF protein with whole-cell vaccines. In a study by Faries et al, 69 patients were vaccinated with Canvaxin, a whole-cell vaccine comprising 3 allogeneic melanoma cell lines and administered with BCG for the first 2 vaccines, and randomized to receive no additional treatment or 200 Kg/m 2 GM-CSF per day on the day of vaccination followed by daily doses for 5 more days. Patients receiving both BCG and GM-CSF had an increased immune response by TA90 IgM antibody titer and increased TA90 immune complexes, but had a diminished delayed-type hypersensitivity (DTH) response to melanoma cells and a trend toward worse survival. 69 It should be noted that at 2 years, the survival of the group receiving the vaccine with BCG, but without GM-CSF, was significantly better (P G 0.002), but with longer follow-up, the difference was no longer significant (P = 0.097). Another phase I trial with an allogeneic breast cancer cell line, MDA-MB-231 expressing CD80, compared 2 doses of GM-CSF at 100 or 50 Kg twice daily for 5 days versus BCG. 53, 54 Four of 9 evaluated patients developed vaccine-specific T-cell responses, and this was split evenly between patients receiving GM-CSF and BCG. Although the number of evaluable patients was small, the patients receiving GM-CSF developed stronger type 1 (IFN-F) vaccinespecific responses, whereas those receiving BCG developed stronger type 2 (IL-5) responses. In addition, a twofold increase in tumor-specific antibody IgG levels was observed in 25% (6/24) of patients, 3 in each of the adjuvant groups. However, 83.3% (5/6) of patients who developed antibody responses were in the groups receiving the largest number of vaccinations (median of 6 vaccines per group). 70 One patient in the cohort receiving high-dose vaccine and GM-CSF had 5% of circulating CD8 T cells capable of specifically producing IFN-F when stimulated with the vaccine. This patient maintained this population for more than 3 years after the last vaccine and has remained disease-free for more than 10 years. 53 The observation of BCG generating a dominant type 2 cytokine response 53,54 may provide a possible explanation for the study of Faries et al, 69 where a worse outcome was observed with patients receiving both BCG and GM-CSF. We postulate that the addition of GM-CSF may have augmented the priming of tumor-specific T cells destined for a nondestructive cytokine (IL-5) profile. Other studies have used daily subcutaneous injections of GM-CSF at the vaccine site. Given the rapid diffusion of GM-CSF away from the vaccine site, this is unlikely to recapitulate the activity observed with GM-CSF geneYmodified tumor cells that provide sustained slow release of cytokine. A number of alternative approaches have been explored to provide local sustained release of GM-CSF, including mini (insulin) pumps, microbeads, polymeric microspheres, and liposomes. 71, 72 In each case where tested, the development of vaccine-induced T-cell responses and anti-tumor immunity is superior with slowrelease GM-CSF when compared with free GM-CSF injected at the vaccine site. Several clinical trials are currently underway, and others are planned using slow sustained release of low-dose GM-CSF. 73 Although the addition of GM-CSF to the vaccine may help cross-priming and expansion of an anti-tumor immune response, the high doses and routes explored were not sufficient to induce a strong anti-tumor immune response in the majority of patients studied.
EVIDENCE TO SUPPORT GM-CSF WITH TOLL-LIKE RECEPTOR SIGNALS
In addition to its positive effects on antigen-presenting cells (APCs), GM-CSF, particularly at high doses, can also have negative effects on immune response generation by inducing myeloid-derived suppressor cells (MDSCs). 74 Granulocyte macrophage colony stimulating factor also can induce milk fat globulin epithelial factor 8 (MFG-E8), which enhances tumor cell survival, invasion, and angiogenesis and augments local immune tolerance. 75, 76 Experiments utilizing GM-CSF j/j mice showed that GM-CSF mediates up-regulation of MFG-E8 on APCs. Milk fat globulin epithelial factor 8Yoverexpressing APCs exposed to apoptotic cells secreted more transforming growth factor A (TGF-A) and less IL-12, resulting in generation of Tregs and inhibition of the T H 1 and T H 17 immune response. 75, 76 This mechanism identified in preclinical models provides insights into how multiple dosing of a GM-CSFYbased vaccine could act as a double-edged sword, not only promoting recruitment of APCs but also limiting the development of a therapeutic immune response. Immunohistochemical analysis of human tumor biopsies has identified MFG-E8 at tumor sites supporting the development of strategies to block this potentially suppressive agent. 76 Toll-like receptor (TLR) agonists have been shown to decrease MFG-E8 expression on CD11b+ MDSC cells and reduce suppressive cytokines TGF-A and IL-6. Therefore, TLR agonists are likely to be important components for GM-CSFYbased vaccination strategies. 75 In a preclinical melanoma model, a copolymer of D,L-lactide and glycolide matrices was mixed with tumor lysate and GM-CSF to provide continuous release of GM-CSF and tumor antigen at the vaccine site. An approximately 3.5 mg/kg dose of GM-CSF reduced recruitment of DCs in tissue compared with a lower GM-CSF dose (È1.5 mg/kg). Importantly, when the low dose of GM-CSF was combined with in situ TLR9 agonist (CpG), DC recruitment increased, resulting in enhanced CTL activity and improved protection against tumor, compared with either treatment alone. 77 Adding a CpG agonist to clinical vaccine trials has also improved immune responses in patients with cancer. In a phase II trial for cutaneous melanoma with MAGE-A3 vaccination, 75 patients were randomized to receive MAGE-A3 combined with either CpG, MPL, and QS21 (AS15) or MPL and QS21 (ASO2B). The AS15 (with CpG) vaccine formulation resulted in an objective clinical response in 3 patients (11Y24 months) and 1 partial response (5 months) compared with only 1 partial response with MAGE-A3 combined with MPL and QS21 without CpG (ASO2B). 78 The CpG cohort saw increased CD4 T-cell responses in 72% of patients compared with only 36% of patients when the vaccine lacked CpG. The CpG cohort also developed higher antiYMAGE-A3 antibody titers. In another vaccine trial with 18 patients, the combination of CpG with NY-ESO-1 protein in Montanide resulted in elicitation of humoral, CD4, and CD8 T-cell responses. Immunologic monitoring used NY-ESO-1 peptide pools to determine the percentage of IFN-F+ NY-ESO-1Yspecific CD4 and CD8 T cells; 94.4% (17/18) of patients had a CD4 T-cell response, and 50% (9/18) had a CD8 T-cell response. The numbers were small, but after 3 to 4 vaccines, many patients had a steady increase in the percentage of CD8 precursors in the peripheral blood mononuclear cells, which following in vitro sensitization (IVS) were capable of secreting IFN-F when restimulated with NY-ESO-1 peptides. This effect appeared a bit stronger for CD4 T cells. Even more striking was the increase in NY-ESO-1Yspecific antibody response with each subsequent vaccination. 43 In this setting, multiple vaccinations with CpG and antigen in Montanide continued to provide a boosting effect that was observed following IVS. We find these data convincing, but this monitoring strategy is substantially different than fresh ex vivo monitoring of vaccine-specific immune responses and suggests that the magnitude of the immune response in this study is not as strong as that observed for the study that combined a TLR9 signal (CpG) and a TLR4 signal (MPL) with antigen and saponin. The data from this trial are largely unpublished and have not been subjected to formal peer review; however, our conclusion from the available data is that multiple booster vaccines, particularly when combined with saponin, TLR4, and TLR9 signals, may augment the anti-tumor immune response.
Epitope Spreading and Heterologous Prime Boost
Disis and colleagues 38,39,79 have evaluated epitope spreading in a number of trials. One notable example, the development of immune responses to HER2/neu epitopes that were not present in the vaccine was in a trial combining trastuzumab with a HER2/ neu helper peptide vaccine. Epitope spreading correlated with an increase in a vaccine-specific T H 1 response and a decrease in serum TGF-A. Multiple trials have reported a relationship between humoral and/or T-cell tumor antigen epitope spreading and clinical outcome. 49 ,80Y84 These studies have reported both epitope spreading within the protein immunogen and interepitope spreading to peptides from entirely different proteins. One method to maximize and focus the immune response to the tumor/tumor associated antigen of choice while avoiding the deleterious effects of vector-specific immunity is through heterologous prime-boost strategies. Heterologous prime boost provides a priming vacci-nation with one vector and comes back with a second ''type'' of vector that shares the same target antigen. This provides a way to maximize and focus the immune response to the tumor/tumor associated antigen of choice while avoiding the deleterious effects of vector-specific immunity. The augmented immune response to the target antigen and the inflammatory response would also support the development of interepitope spreading. In the case of viral vaccine vectors, the humoral response to viral proteins prevents viral entry and infection during secondary vaccination.
One approach to increase the magnitude of the tumorspecific T-cell response is to use a microbial-based vaccine vector expressing 1 or more tumor associated antigens contained within the irradiated tumor cell vaccine or separately in a heterologous prime-boost combination. Priming with whole-cell vaccine elicits a broad T-cell response of limited magnitude, which when boosted by a microbial-based vaccine expressing a defined tumor associated antigen can promote exceptional expansion of T cells specific for the shared antigen. 85 Live-attenuated vectors based on the intracellular bacterium Listeria monocytogenes have performed remarkably in this capacity by introducing the inflammatory environment to induce memory T-cell persistence. 86 In preclinical studies, mice immunized with the whole-cell vaccine, CT26-GVAX, developed primed AH1-vaccineYspecific CD8+ T cells. However, this CD8 T-cell response typically comprised only a fraction of a percent of the total CD8+ T cells (0.1%Y0.3%). Boosting this response with a live-attenuated L. monocytogenes vaccine expressing AH1 expands the AH1-specific CD8 T-cell population nearly 1000fold, 17% to 21% of the total CD8+ T-cell population (unpublished data). One potential caveat of this approach is that T cells specific for epitopes encoded by the boosting vaccine may expand at the expense of T cells recognizing other tumor associated antigens. 87 In this scenario, the breadth of the T-cell response could be lost, and the benefits of a whole-cell vaccine minimized.
Viral vectors have also been used successfully as vaccines. A recent study using a heterologous subcutaneous prime with rhesus cytomegalovirus vector expressing simian immunodeficiency virus (SIV) followed by heterologous boost with adenovirus 5 expressing SIV antigens protected against SIV infection by increasing viral-specific memory CD8 and CD4 T cells. 88 In this instance, the heterologous prime-boost strategy did not add to the strong and persistent immune response induced by the rhesus cytomegalovirus alone, suggesting that CMV may provide unique advantages as a vector for delivering cancer vaccines.
Prostate-specific antigen (PSA)YPROSTVAC is a prostate vaccine consisting of a priming vaccination with recombinant vaccinia expressing 4 PSA genes followed by boosting vaccination with a fowl pox vector expressing the same genes. Phase II clinical trials using PSAYPROSTVAC in metastatic prostate cancer improved median overall survival by 8.5 months compared with patients treated with empty vector. 89 A twofold increase in PSA-specific IFN-F production was seen in 44.8% of the patients after vaccination, and patients with strong IFN-F responses had more than sixfold increase in survival when compared with those who did not make a response (P = 0.055). 48 Another prime-boost strategy was recently reported by Ribas et al 37 ; in this case, the priming vaccination included 4 intraY lymph node injections of a plasmid encoding 4 epitopes for melan-A and tyrosinase with 2 subsequent boosts with peptide analogs. A high dose (300 Kg) and low dose (100 Kg) of boosting peptide were studied with similar frequency of antigenspecific responses observed in the evaluable patients (75% vs 67%). Although the numbers of patients evaluated were small, the immune response rate was twice that when using only intranodal peptide. 90 Heterologous prime boost with the proper adjuvants may expand an existing immune response and potentially generate a de novo response; however, determining timing, location, and type of prime-boost vaccination may be important for inducing persistent anti-tumor immunity.
IMMUNOGENIC DEATH ENHANCES VACCINE EFFICACY
Immunogenic cell death is important to elicit TLR signaling. This type of death is considered ''immunogenic'' because it supports cross-presentation of tumor antigens to APCs by inducing proteins and chaperones that deliver dying cells to APCs for phagocytosis. 91, 92 As an example, the protein high mobility group box 1 is expressed upon immunogenic tumor death and interacts with TLR4 receptor on APCs. Interestingly, a polymorphism in the TLR4 (N299G) gene decreases responsiveness to high mobility group box 1 activation of APCs, and this loss of function corresponds to an increased likelihood of drug-resistant relapse for patients with breast cancer. 92 Screening for this mutation before vaccination could signal a requirement to add other TLR agonists or adjuvants to the vaccine. Immunogenic cell death also stimulates natural killer and cytotoxic lymphocytes by increasing expression of natural killer group 2, member D (NKG2D). However, tolerogenic cellular death induced by certain types of DNA damage can lead to shedding of the NKG2D ligand MHC class I chainYrelated protein A (MICA). 91, 93 Activation of NKG2D on natural killer and CD8 T cells induces tumor destruction, but when NKG2D ligands, such as MICA, are shed, they down-regulate NKG2D and induce immune suppression. 94 Serum levels of soluble MICA ligand have been associated with worse prognosis in patients with multiple myeloma and decreased responsiveness to ipilumumab treatment in patients with advanced melanoma. 85, 95, 96 Melanoma patients receiving 6 vaccinations with autologous tumor cells transduced to secrete GM-CSF followed by ipilumumab treatment exhibited significant humoral response to MICA. These anti-MICA antibodies functionally destroyed tumors via complement fixation and opsonization. This suggests that vaccination with MICA may be a candidate for combination therapy with cytotoxic agents and vaccination. 96 
CHEMOTHERAPY AND RADIATION IN COMBINATION WITH VACCINATION
Chemotherapy and radiotherapy, by eliciting immunogenic cell death, are important tools for combination with immunotherapy. The cytotoxic agents, oxaliplatin, irinotecan, docetaxel, doxorubicin, and irradiation, have all been shown to induce immunogenic cell death in preclinical models. 91 In addition to direct anti-tumor effects that may provide a source of antigen for cross-presentation, they can reduce Tregs and MDSCs, mediate release of TLR signals from the gut, and induce lymphopenia, creating space for improved antigen-driven expansion of vaccine-reactive T cells. 97 Jaffee and colleagues 98 administered a vaccine composed of 2 allogeneic pancreatic cancer cell lines, PANC10.05 and 6.03, genetically modified to secrete GM-CSF, before initiation of chemoradiation therapy. Booster vaccines were administered at monthly intervals, 8 weeks after chemoradiotherapy. Twenty-one percent (3/14) of patients remain disease-free 10 years after vaccination. The 3 surviving patients all exhibited a DTH response to autologous tumor. 98 Recently, a single institution phase II trial using the same strategy for 60 patients included further anti-tumor immune monitoring by measuring the antimesothelin response. The overall population had mesothelin-specific CD8 T cells following 1 vaccination, but this response waned after 5 vacci-nations. Patients who were HLA-A1 or HLA-A2 maintained a substantially stronger antimesothelin response after 5 vaccinations, which correlated with disease-free survival, 99 suggesting that people with certain HLA types respond differently to multiple vaccinations.
Another trial looked at the effect of combination treatment with cyclophosphamide, which is known to induce immunogenic death, and vaccination with an allogeneic GM-CSFYsecreting vaccine for pancreatic cancer (CG8020/CG2505). Survival with vaccination alone was 2.3 months, whereas cyclophosphamide (250 mg/m 2 ) given 1 day before vaccination increased survival to 4.3 months. 100 Some of the most successful trials with allogeneic GM-CSF vaccination have been seen with combination therapy for liquid tumors. In the case of imatinib-resistant chronic myeloid leukemia, 4 vaccinations with the allogeneic K562/GM-CSF cell line, given at 3-week intervals with or without imiquimod adjuvant, decreased BCR-Abl expression; 7 patients had undetectable disease by polymerase chain reaction. 101 In addition, K562/GM-CSF vaccination in combination with autologous stem cell transplant for treatment of acute myeloid leukemia induced a DTH response and demonstrated a 3-year relapse-free survival of 61.8%. Patients also received cytarabine, daunorubicin, busulfan, and cyclophosphamide, which may also have contributed to the lasting anti-tumor immune response, evidenced by IFN-F and granzyme B production. 102 A phase I dose-escalation study used HER2-positive allogeneic breast cancer lines transduced to secrete GM-CSF as a vaccine, alone or combined with simultaneous administration of low-or high-dose cyclophosphamide and doxorubicin. Whereas the higher-dose chemotherapy eliminated the humoral immune response, the low-dose chemotherapy augmented the anti-HER2 antibody responses. 103 In another study, pretreatment with 300 mg/m 2 cyclophosphamide reduced progression of breast carcinoma when used in conjunction with a vaccine against mucin antigen, sialyl-Tn, with a projected median survival of 19.7 versus 12.6 months with vaccine alone (P = 0.0176). 104 In a pilot study for treating prostate cancer with a combination therapy of radiation, GM-CSF, and IL-2, with or without vaccination with a fowl pox viral vector containing PSA and costimulatory molecules, 76% (13/17) of patients vaccinated had a PSA-specific T-cell response, with no detectable PSAspecific T cells in the nonvaccinated group. 105 
ADDITIONAL STRATEGIES TO AUGMENT THE IMMUNE RESPONSE TO BOOSTER VACCINES
Vaccination regimens also have the capacity to induce immunosuppressive mechanisms including Tregs, MDSCs, IL-10Yproducing B cells (B10), and an anti-inflammatory cytokine environment, which work against the goal of immune response induction.
Regulatory T Cells
A high frequency of circulating Tregs has been seen in patients with lung, ovarian, breast, colorectal, esophageal, gastric, hepatocellular, leukemia, lymphoma, melanoma, and pancreatic cancers (reviewed by Zou 106 in 2006) . This increase in Tregs, particularly within the tumor, has been associated with poor prognosis. 107 Preclinical and clinical trials have tried to eliminate Tregs in combination with vaccination. In a phase I trial, 3 vaccinations with an NY-ESO-1 DNA vector were administered every 4 weeks; 93% (15/16) of patients developed a vaccine-specific response, and in vitro data suggested that this tumor-specific response was inhibited by Tregs. 108 In preclinical studies, 3 vaccinations with a whole-cell vaccine secreting GM-CSF decreased therapeutic efficacy and increased Treg numbers. When CD4 cells were partially depleted before the second and third vaccinations, anti-tumor immunity was restored, identifying CD4 depletion as a method to decrease Tregs. 8 This could be rapidly translated to clinical trials, as there is a humanized CD4-depleting antibody zanolimumab (Hu-max-CD4), which has been used to treat cutaneous T-cell lymphoma. This antibody is being used in combination with IL-2 in a phase II clinical trial to reduce Tregs. 109, 110 In preclinical models, CD4 depletion has increased anti-tumor immune responses; however, some level of CD4 T-cell help is likely critical for priming and maintenance of memory CD8 T cells, and depletion of the beneficial CD4 T cells could be detrimental to long-term immunity. 111, 112 Other methods have been used to target Tregs, including CD25 blockade or depletion and small molecule inhibitors of TGF-A. Human Tregs express high levels of IL-2R>, CD25. Two types of CD25-targeted antibodies have been used to reduce Treg numbers in cancer patients. The humanized monoclonal CD25-blocking antibody, daclizumab, has been used to reduce Treg function in multiple clinical trials. The best results were seen in a trial where patients received daclizumab 1 week before 5 vaccinations with hTert or survivin peptides plus GM-CSF, which resulted in an antigen-specific CTL response. 113 Another CD25-targeted therapy, the immunotoxin denileukin diftitox (ONTAK) is a fusion protein of IL-2 coupled with the active enzyme of diphtheria toxin. ONTAK was originally developed for treating T-cell lymphoma; however, it is currently being used in combination with vaccination as a method to reduce Tregs in ovarian, breast, lung, and renal carcinoma. 114Y116 Renal cell carcinoma patients who were pretreated with ONTAK followed by vaccination with DCs transfected with tumor RNA exhibited a 7.2-and 7.9-fold median increase in CD4 and CD8 T-cell responses against RNA-transfected DCs, respectively. 114 There are a number of pitfalls to CD25-depletion strategies. First, CD25 not only is expressed on Tregs, but also activated CD4 and CD8 effector T cells, and eliminating these cells can eliminate important tumor-reactive T cells; second, these CD25depletion strategies do not always significantly reduce Treg numbers when confirmed by FOXP3 expression. 117Y119 Finally, CD25 is expressed on APCs involved in IL-2 signaling to T cells, and depletion/blocking of these APCs decreases T-cell activation. 120 Furthermore, the role of CD25 might be drastically different in mice and humans. In mice, CD25 depletion results in loss of tolerance, whereas in humans it causes immunodeficiency, indicating that mouse CD25-depletion models may not predict the clinical outcome of CD25-blockade. 121Y123 Supporting this concept, a phase I/II trial combining vaccination with tumor-antigen pulsed DCs with prior blockade using daclizumab found no difference in progression-free survival compared with vaccination alone. 117 Regulatory T cell suppression may be reduced by targeting induction of new Tregs. Transforming growth factor A, which is secreted by many tumors, suppresses effector T cells and induces Tregs and tumor-activated macrophages. 124 SM16, a smallmolecule inhibitor of TGF-A type 1 receptor (ALK5) kinase, has been shown to decrease mesothelioma recurrence and decrease metastatic breast cancer pathology by altering anti-tumor immunity. 125, 126 These studies suggest that systemic TGF-A inhibition may be a promising addition to combination immunotherapy strategies.
Myeloid-Derived Suppressor Cells
The tumor environment induces the development of MDSCs, which have been shown to down-regulate IFN-F expression, increase Tregs, and decrease anti-tumor immunity. 127, 128 Granulocyte macrophage colony stimulating factorYsecreting vaccines also induce MDSC accumulation and induction in both the tumor microenvironment and periphery. 74 In preclinical models and in vitro human studies, all-trans-retinoic acid increases anti-tumor immunity to vaccination by directly reducing myeloid suppressor cells. 128, 129 Phosphodiesterase 5 (PDE-5) inhibitors also inhibit MDSC function. When PDE-5 blockade was administered the same day as tumor challenge, it prevented 50% to 70% of tumor growth in a number of different preclinical tumor models. 130 A phase I clinical trial combining telomerase vaccination with GM-CSF and tadalafil will examine the role of PDE-5 inhibitors in combination therapy for pancreatic cancer. 109
IL-10YProducing B Cells (B10)
The role of B10 cells in the anti-tumor response is not completely clear, although evidence suggests that tumor-induced B cells inhibit CD8 T-cell proliferation, reduce IFN-F and IL-2 production, and induce Tregs causing progression of metastatic breast cancer. 131, 132 B-cellYdeficient mice have reduced Tregs and increased anti-tumor immunity; however, preclinical studies have shown that depletion of B cells with anti-CD20 antibodies can also decrease effector T-cell number and function. 133, 134 One possible explanation for this effect is the depletion of antigen-presenting B cells that may be beneficial to anti-tumor immunity. 133, 135 Rituximab, the FDA-approved B-cellYdepleting antibody is certainly a contender for B10 depletion studies; however, new therapies designed to target B10-producing cells specifically would be useful.
CYTOKINE ADMINISTRATION CAN IMPROVE ANTI-TUMOR INFLAMMATORY CONDITIONS
The cytokine environment in the tumor can vastly alter the immune response. Therefore, exogenous treatment with immune-stimulating cytokines is an attractive avenue of combination treatment with vaccination. A recent phase III clinical trail comparing IL-2 treatment plus gp100 peptide vaccination to IL-2 treatment alone for metastatic melanoma reported improved overall response rates, as well as increased progressionfree survival. 136 Although the mechanisms responsible for this effect are unclear, it suggests additional strategies to improve vaccine efficacy.
Interleukin 7 is important for homeostasis of naive and memory T cells. 137 Treatment with IL-7 has been shown to protect against viral infection and increase CD8 T-cell numbers. 138 We recently demonstrated its ability to enhance antigendriven proliferation of tumor-specific T cells and inhibit the suppressive effect of CD8+CD122+ Tregs. 139 Initial toxicity trials have shown very little toxicity in patients with refractory cancer, and in combination with MART-1 and gp100 peptide vaccination, IL-7 increased the number of CD4 and CD8 T cells and reduced the numbers of Tregs, in a dose-dependent manner. 140, 141 Interleukin 15 is an important cytokine for activation and proliferation of NK and T cells, as well as increasing memory T-cell response during vaccination. 142, 143 T cells activated ex vivo in the presence of IL-15 before adoptive immunotherapy exhibit enhanced therapeutic efficacy in a number of preclinical tumor models. 144Y146 Therefore, administration of recombinant IL-15 has potential combined with vaccination and is currently being tested in phase I clinical trials. Furthermore, chimeric constructs of IL-15R>YIgGYFc, which stabilizes IL-15 signaling, and enhances anti-tumor activity are being developed for clinical trials. 147 Interleukin 21 is also an attractive candidate for combination therapy because of its ability to induce memory stem cells. 148 Administration of IL-21 decreases Tregs in the tumor microenvironment and suppressor Treg function. 149Y151 Fourteen stage IV melanoma patients treated with human rIL-21 at 30 Kg/kg per day for 5 cycles showed 1 CR and 1 partial response and experienced very little toxicity. 152 This early study underscores the potential rIL-21 has for combination therapy.
NEW SOURCES OF ANTIGENS FOR TUMOR VACCINATION
Whole tumor cell vaccines contain the full spectrum of unique and shared antigens that the immune system might recognize in the development of a therapeutic immune response. In reality, whole-cell vaccines likely result in recognition of only long-lived proteins that survive long enough to be crosspresented to the immune system by APCs. 153 It has been postulated that as a consequence of their being long-lived, many of these self-proteins have already been cross-presented under noninflammatory conditions, resulting in the induction of immunologic tolerance to these antigens in the periphery. In contrast, short-lived proteins (SLiPs) or defective ribosomal products (DRiPs), because they are so rapidly degraded by the proteosome and shuttled to the membrane in class I molecules, represent excellent tumor targets, but are not available to be cross-presented by the APC. 154 Thus, peripheral tolerance is less likely induced against these SLiPs, while at the same time these SLiPs and DRiPs may comprise the majority of targets being presented by MHC. 155 Li et al 156 pioneered a strategy that exploits proteosome blockade, which leads to accumulation of SLiPs and DRiPs in autophagosomes, to develop a new vaccine with therapeutic efficacy superior to GM-CSFYsecreting vaccines. Subsequently, Twitty et al 157 documented that this autophagosome vaccine strategy could challenge a well-established paradigm in tumor immunology that has stood for 50 years. Specifically, they showed that vaccination with a unique, chemically induced sarcoma protected animals against a challenge with the sarcoma used for the vaccine, but not from a challenge with other related sarcomas. In contrast, when autophagosomes were used for vaccination, a proportion from 1 tumor not only protected against the immunizing tumor but also provided significant cross-protection from a challenge with other sarcomas in 8 of 9 combinations tested. Whole tumor cells provided no significant cross-protection in any of the same 9 combinations. It will be interesting, and potentially clinically relevant, to identify the SLiPs that serve as cross-reactive antigens in these models. These promising preclinical results highlight the potential that new sources of ''nontolerant'' shared antigens may have on the effectiveness of cancer vaccines. A clinical trial of this strategy has been initiated in patients with NSCLC.
DISCUSSION
The observation that high frequencies (95%) of tumorspecific T cells in the peripheral blood correlate with objective clinical response in adoptive immunotherapy studies has provided a bar for proof of concept to establish what might be required to achieve objective clinical responses using cancer vaccines. 158 However, the majority of clinical trials never identify this level of T-cell response in vaccinated patients. In these studies, it is an order of magnitude less. Does this explain the limited success of cancer vaccines? Is it possible that current vaccine strategies that include boosting actually attenuate the anti-tumor immune response?
It is interesting that the first FDA-approved therapeutic vaccine recommends only 3 vaccinations. 159 Although detailed immunologic monitoring results from this novel vaccine strategy have not been published, data presented at the Society for the Immunotherapy of Cancer (SITC)YNational Cancer Institute (NCI) Workshop and available on the SITC Web site document a significant correlation (P G 0.049) between a positive ELISpot response to the fusion protein target antigen (prostate-associated membrane antigen) contained in the vaccine and overall survival (www.sitcancer.org/meetings/am10/biomarkers10/65). Although it is unclear how an immune response to a novel fusion protein impacts the anticancer immune response, it seems plausible that a strong immune response to the foreign fusion protein may have led to spreading of an immune response against other relevant tumor targets.
Regarding the question of whether multiple vaccinations are friend or foe, a review of the clinical trials summarized in Table 1 provides a mixed picture. In some cases, there was evidence that boosting augmented an antigen-specific immune response. 35,36,43Y46,50,51,56 Other studies with altered peptide ligands induced strong immune responses to a single epitope, but did not provide protection from tumor recurrence. 31 Even in studies where large percentages of patients generated vaccine-specific responses, the magnitude of response frequently decreased, sometimes even despite additional vaccinations. 40, 48, 63, 64, 69, 82 Combining tumor-specific CD4 epitopes did not uniformly help and in some cases significantly hindered tumor-specific response. 32, 160 Explanations for the limited effects of cancer vaccine boosters are unclear, but numerous possibilities exist. To start, we acknowledge that in 2011 the immunotherapy community is still uncertain about the immune parameters that should be viewed as correlates with clinical response. A recent report from the International Society for Biological Therapy of CancerYSITC/FDA/NCI Workshop on Immunotherapy biomarkers recognized that ''Despite substantial efforts from many groups, we do not know which parameters of immune responses, and which assays used to assess these parameters, are optimal for efficacy analysis. Indeed, the tumor-specific cellular immune response promoted by immunization often has not correlated with clinical cancer regression despite the induced cytotoxic T cells detected in in vitro assays.'' 161 Another limitation to identifying immune biomarkers that correlate with clinical response is the low response rate to current cancer vaccine strategies. The recent report of Kirkwood et al; 35 showing a statistically significant correlation between development of a vaccine-induced immune response and increased overall survival, provides encouragement that it will be possible to identify, in the peripheral blood, a clinically relevant biomarker for response.
The strongest support for booster vaccines augmenting anticancer immune responses is found in trials where immunologically active or complementary treatments were combined with the vaccine strategy, but even here, augmentation of the anticancer immune response was not universal. 43, 49, 54, 78, 103, 104, 113, 114 The immunologic status at the host-cancer interface may provide an explanation for these results. Studies by Galon et al 162 reported that intra-tumor CD3+ T cells and cells at the invasive margin correlated with tumor stage and patient outcome; moreover, this was correlated with CD45RO expression, a marker associated with memory T cells. Galon's group also reported that a T H 1 hi (Tbet, IRF1, IL12Rb2, STAT4) T H 17 low (RORC, IL17A) gene profile correlated with disease-free survival. 163 Identifying immunologic ''signatures'' associated with favorable prognosis is an active area of investigation and may identify patients most likely to benefit from a vaccination strategy that ultimately boosts their endogenous response. In addition to colorectal cancer, disease survival in women with epithelial ovarian cancer has also been positively associated with intratumoral expression of CD8, CD3, FoxP3, TIA-1, CD20, and MHC classes I and II. 164 Furthermore, estrogen receptor-negative breast cancer patients with an 8-gene mRNA signature of CD19, CD3D, CD48, GZMB, LCK, MS4A1, PRF1, and SELL within TIL had improved disease-free survival after treatment with adjuvant anthracycline-based therapy (N. West, et al, written correspondence August 16, 2011) . Melanomas that express the chemokines, CCL2, CCL3, CCL4, CCL5, CXCL9, and CXCL10, had increased infiltration of CD8 T cells, indicating that tumor chemokine expression is associated with lymphocyte infiltration. 165 These immune characterizations have moved from retrospective analyses and are now integrated into the original clinical trial design as prospective biomarkers. One phase II trial in NSCLC selected patients by gene expression profiling before comparing vaccination with MAGE-A3 plus adjuvant and placebo. Patients with a predictive signature exhibited improved clinical outcome. 166 This trial has moved to phase III, and the signature is being evaluated in metastatic melanoma patients. We hypothesize that patients with positive immune signatures respond significantly better to vaccination because they do not require the priming of a new anticancer immune response, simply a boosting of the existing response ( Fig. 1A) . On the contrary, patients who have not generated an anticancer immune response, as measured by an absence of immune effector and suppressor cells (Fig. 1B) , do less well clinically because the current vaccine strategies are not effective at priming of a de novo anticancer immune response. In contrast, patients with an immunosuppressive signature (Fig. 1C) would require combination therapies that first target the culprits of negative regula-tion, in addition to providing effective priming and costimulatory signals. Although Figure 1 separates the immune signatures into 3 groups, we appreciate that in most patients there is likely to be a continuum of immune response over time and/or that all 3 might be represented at different metastatic sites in the same patient.
Our interpretation of the immune signature data is that failure to consider innovative combination approaches in the cohort of patients identified in panels B and C (Fig. 1 ) will lead to limited success. Although controversial, we consider the goal of inducing a 5% level of cancer-reactive circulating T cell to be an obtainable benchmark for cancer vaccines. To obtain this magnitude of response in a large fraction of patients will require tailoring the therapy to the patient based on his/her immunologic signature as well as his/her genetic profile. The availability of a wide range of novel immunologically active agents provides many possibilities. Improved understanding of the complex mechanism of action of adjuvants, such as GM-CSF, has provided insights into how they might be administered more effectively and how and with what they might be combined to optimize anticancer immune-stimulating activities while blocking negative regulators. The discovery of classes of tumor antigens that are not typically cross-presented and thus less likely to have established peripheral immune tolerance may provide a novel source of targets for a next generation of cancer vaccines. The availability of a host of agents that interfere with suppressive activities provides agonistic costimulatory, or checkpoint blockade must also play a critical role in the next generation A, An active immune signature identified by phenotypic or genetic analysis of immune components within the tumor signal preexisting immune response that is easier to augment by booster vaccines. This is the cohort of patients who respond to effective boosting vaccines. B, Tumors that lack an immune signature contain few immune cells, signaling the lack of an anti-tumor immune response. Vaccine strategies need to stress both priming of a de novo anti-tumor immune response as well as boosting of the immune response to be effective. C, Immunosuppressive gene signature including Tregs, MDSCs, regulatory B cells, and/or tolerogenic cytokines will block the immune response to vaccination and may have eliminated tumor-specific T cells. Vaccine strategies need to start with elimination of the suppressive environment/cells and subsequently prime and boost the anti-tumor immune response to develop a therapeutic immune response. All 3 scenarios are expected to benefit from agents that induce immunogenic death. of cancer immunotherapies. The cancer immunotherapy field recognizes that combination therapies offer much promise for improving patient outcomes and have identified the inability to obtain reagents to perform combination immunotherapy clinical trials as one of the leading hurdles to successful immunotherapy. 167 An international consortium of 11 societies and associations have joined together as the World Immunotherapy Council to begin addressing these hurdles that include the accessibility of agents from commercial sources, funding for performing and monitoring of clinical trials, and developing the next generation of translational research teams that will integrate these strategies into a comprehensive personalized approach for patients with cancer. 167 The Cancer Immunotherapy Network is another recently established force, supported by the NCI, which is diligently working to initiate clinical trials of combination immunotherapy. 168Y170 In conclusion, the immunologic monitoring data obtained from clinical trials to date have been too limited to determine whether multiple vaccinations are beneficial. Nonetheless, it is clear that the current vaccine strategies have been generally ineffective; they lead to weak immune responses and low response rates. The availability of immunologically active agents and the appreciation that vaccines may, via epitope spreading, induce immune responses to targets not included in the vaccine, coupled with novel technologies to monitor the development of immune responses to those unknown targets, promise to guide the future development of clinical immunotherapy strategies. 171 We suggest that characterizing the immune signature of each patient's cancer coupled with the utilization of improved methods to assess the vaccine-induced immune response will help distinguish the benefits and detriments of multiple vaccinations. Ultimately, these refinements coupled with access to novel immunologically active agents will lead to stronger immune responses to cancer vaccines and substantial improvements in the outcomes of patients with cancer. 
